首页> 外文期刊>Cell and Tissue Research >Status and perspectives of neuroprotective therapies in glaucoma: The European Glaucoma Society White Paper
【24h】

Status and perspectives of neuroprotective therapies in glaucoma: The European Glaucoma Society White Paper

机译:青光眼神经保护疗法的现状和观点:欧洲青光眼学会白皮书

获取原文
获取原文并翻译 | 示例
           

摘要

Glaucoma, a chronic progressive neuropathy and the most frequent cause of irreversible blindness worldwide, is commonly treated by medication or surgery aimed at lowering intraocular pressure. In view of the limited therapeutic options, the European Glaucoma Society (EGS) sponsored two Think Tank Meetings with the goal of assessing the current status and the overall perspectives for neuroprotective treatment strategies in glaucoma. The results of the meetings are summarized in this EGS White Paper.
机译:青光眼是一种慢性进行性神经病,是世界范围内不可逆性失明的最常见原因,通常通过旨在降低眼内压的药物或手术治疗。鉴于治疗选择的局限性,欧洲青光眼学会(EGS)主办了两次智库会议,旨在评估青光眼神经保护治疗策略的现状和总体观点。会议结果在此EGS白皮书中进行了概述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号